Skip to main content
Premium Trial:

Request an Annual Quote

AmoyDx Lung Cancer CDx Approved in South Korea

NEW YORK (GenomeWeb) — Chinese diagnostics firm AmoyDx announced this month that South Korea's Ministry of Food and Drug Safety has approved its ROS1 fusion assay as a companion diagnostic for Pfizer's non-small cell lung cancer (NSCLC) drug Xalkori (crizotinib).

Xalkori inhibits the oncogenes ROS1 and ALK. AmoyDx's PCR-based assay identifies 14 ROS1 gene fusions by analyzing tumor messenger RNA from human tumor tissue or body fluids, providing results in around 2.5 hours. AmoyDx noted that ROS1 gene rearrangements occur in about 2.4 percent of Asian NSCLC patients.

The assay received CE marking in 2013. It was approved by China's Food and Drug Administration in 2014 and in Japan in 2017.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.